ZNF692 Promotes the Progression of Colon Adenocarcinoma by Regulating HSF4 Expression
Abstract
Background: Colon adenocarcinoma (COAD) is one of the most common cancer happened in gastrointestinal tract, with the overall incidence rate of 4%-5% among human beings. Like most malignancies, we uncovered the exact mechanisms of the pathogenesis of colorectal cancer yet. Therefore, there is an urgent need to explore the molecules that can be used as diagnostic maker at early stage. In addition, we also need to define the essential factors that related to the prognosis and treatment of the colon carcinoma.
Methods: The study was conducted at the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China in September 2020. The R language was used to identify the differentially expressed genes. We performed receiver operating characteristic curve analysis to determine the diagnostic markers for COAD. The machine learning strategy was used to assess the effectiveness of genes in the diagnosis of COAD. The molecular mechanism and prognostic value of genes were explored by bioinformatics analysis and molecular experiments.
Results: The expression level of heat shock factor 4 (HSF4) was significantly elevated in COAD patients (P=1.89×10-29), according to The Cancer Genome Atlas (TCGA) database. Additionally, survival analysis showed the higher expression level of the HSF4 was correlated with the poor prognosis in COAD.
Conclusion: The HSF4 was the target gene of zinc finger protein 692(ZNF692). HSF4 might promote the progression of COAD through the apoptosis pathway. It was diagnostic and prognosis maker of COAD. Furthermore, the upstream gene of HSF4, ZNF692, promotes the progression of colorectal cancer by regulating HSF4 expression.
2. Edwards BK, Ward E, Kohler BA, et al (2010). Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 116:544–573.
3. Hao Y, Wang Y, Qi M, He X, Zhu Y, Hong J (2019). Risk factors for recurrent colo-rectal polyps. Gut Liver, 14:399-411.
4. Pohl C, Hombach A, Kruis W (2000). Chronic inflammatory bowel disease and cancer. Hepatogastroenterology, 47:57–70.
5. Mehta A, Patel BM (2019). Therapeutic op-portunities in COAD: Focus on phos-phodiesterase inhibitions. Life Sci, 230:15-161.
6. Valdivia MM, Hamdouch K, Ortiz M, Asto-la A (2009). CENPA a genomic marker for centromere activity and human dis-eases. Curr Genomics, 10(5):326-35.
7. Howman EV, Fowler KJ, Newson AJ, et al (2000). Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. Proc Natl Acad Sci U S A, 97(3):1148-53.
8. Heun P, Erhardt S, Blower MD, Weiss S, Skora AD, Karpen GH (2006). Mislocali-zation of the Drosophila centromere-specific histone CID promotes for-mation of functional ectopic kineto-chores. Dev Cell, 10(3):303-15.
9. Shrestha RL, Ahn GS, Staples MI, et al (2017). Mislocalization of centromeric histone H3 variant CENP-A contributes to chromosomal instability (CIN) in human cells. Oncotarget, 8(29):46781–46800.
10. Zhang W, Mao JH, Zhu W, et al (2016). Centromere and kinetochore gene mi-sexpression predicts cancer patient sur-vival and response to radiotherapy and chemotherapy. Nat Commun, 7:12619.
11. Zhang W, Karpen GH, Zhang Q (2017). Exploring the role of CENP-A Ser18 phosphorylation in CIN and tumor-igenesis. Cell Cycle, 16(24):2323–2325.
12. Sharma AB, Dimitrov S, Hamiche A, Van Dyck E (2019). Centromeric and ectopic assembly of CENP-A chromatin in health and cancer: old marks and new tracks. Nucleic Acids Res, 47(3):1051-1069.
13. Sullivan LL, Boivin CD, Mravinac B, Song IY, Sullivan BA (2011). Genomic size of CENP-A domain is proportional to total alpha satellite array size at human cen-tromeres and expands in cancer cells. Chromosome Res, 19(4):457-70.
14. Athwal RK, Walkiewicz MP, Baek S, et al (2015). CENP-A nucleosomes localize to transcription factor hotspots and sub-telomeric sites in human cancer cells. Epigenetics Chromatin, 8:2.
15. McGovern SL, Qi Y, Pusztai L, Symmans WF, Buchholz TA (2012). Centromere protein-A, an essential centromere pro-tein, is a prognostic marker for relapse in estrogen receptor-positive breast can-cer. Breast Cancer Res, 14(3):R72.
16. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN es-timates of incidence and mortality worldwide for 36 cancers in 185 coun-tries. CA Cancer J Clin, 68(6):394–424.
17. Arnold CN, Goel A, Blum HE, Boland CR (2005). Molecular pathogenesis of colo-rectal cancer: implications for molecu-lar diagnosis. Cancer, 104(10):2035–2047.
18. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR (2017). The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of COAD. Dis Colon Rec-tum, 60(10):999–1017.
19. Jones S, Chen WD, Parmigiani G, et al (2008). Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A, 105(11):4283–4288.
20. Jeffery M, Hickey BE, Hider PN (2019). Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev, 9:CD002200.
21. Xing Y, Zhao Z, Zhu Y, Zhao L, Zhu A, Pi-ao D (2018). Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identifica-tion of a 14-lncRNA prognostic signa-ture for patients with colon adenocarci-noma. Oncol Rep, 39:2365–2375.
22. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A (1997). Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tu-mours. Nature, 389:876–881.
23. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P (2001). The ZNF217 gene amplified in breast can-cers promotes immortalization of hu-man mammary epithelial cells. Cancer Res, 61:1250–1254.
24. Imoto I, Yuki Y, Sonoda I, et al (2003). Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas. Cancer Res, 63:5691-5696.
25. Jiang R, Wang JC, Sun M, Zhang XY, Wu H (2012). Zinc finger X-chromosomal pro-tein (ZFX) promotes solid agar colony growth of osteosarcoma cells. Oncol Res, 20:565–570.
26. Lai KP, Chen J, He M, et al (2014). Overex-pression of ZFX confers self-renewal and chemoresistance properties in hepatocellular carcinoma. Int J Cancer, 135:1790–1799.
27. Fang X, Huang Z, Zhou W, et al (2014). The zinc finger transcription factor ZFX is required for maintaining the tumorigen-ic potential of glioblastoma stem cells. Stem Cells, 32:2033–2047.
28. Yan X, Shan Z, Yan L, et al (2016). High expression of Zinc-finger protein X-linked promotes tumor growth and pre-dicts a poor outcome for stage II/III colorectal cancer patients. Oncotarget, 7:19680–19692.
29. Robinson MD, McCarthy DJ, Smyth GK (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformat-ics, 26:139–140.
30. Edge SB, Compton CC (2010). The Ameri-can Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol, 17:1471–1474.
| Files | ||
| Issue | Vol 52 No 12 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i12.14321 | |
| Keywords | ||
| Colon adenocarcinoma Biomarker Heat shock factor 4 Zinc finger protein 692 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
